LS

Lite Strategy, Inc.

LITS·NASDAQ

$1.43

-3.5%
HealthcareBiotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$52.60M
EPS-2.3900
P/E Ratio-1.89
Earnings Date02/11/2026

lits

Deferred Revenue

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LS

Lite Strategy, Inc. Competitors Analysis of Deferred Revenue

LITS · NASDAQ
CompanyDeferred Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
0.00
N/AN/AN/A
33.73M
N/AN/AN/A
0.00
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
68.00K
N/AN/A-31.3%
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
LS

Lite Strategy, Inc. Fair Value Envelope

LITS · NASDAQ

Our analysis suggests that LITS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.43, this represents a potential HIDDEN relative to our calculated worth for Lite Strategy, Inc..

Intrinsic Value
Current Price: $1.43